Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ATH 434

Next Previous
Search
Drug Profile

ATH 434

Alternative Names: ATH-434; PBT 434

Latest Information Update: 17 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Prana Biotechnology
  • Developer Alterity Therapeutics
  • Class Amines; Antiparkinsonians; Chlorinated hydrocarbons; Neuroprotectants; Quinazolinones; Small molecules
  • Mechanism of Action Alpha-synuclein inhibitors; Iron chelating agents; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple system atrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple system atrophy
  • Research Friedreich's ataxia
  • No development reported Parkinson's disease

Most Recent Events

  • 10 Apr 2025 Efficacy data from phase-II ATH434-201 trial in Multiple system atrophy released by Alterity Therapeutics
  • 26 Feb 2025 Alterity Therapeutics completes phase-II trial in Multiple system atrophy in USA (PO) (NCT05864365)
  • 30 Jan 2025 Efficacy and adverse events data from phase-II ATH434-201 trial in multiple system atrophy released by Alterity Therapeutics

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top